CJC-1295 NO DAC

CJC-1295 NO DAC Molecular Structure & Chemical Properties

CJC-1295 NO DAC peptide represents one of the most extensively studied growth hormone secretagogue peptides in preclinical research, with investigations spanning over two decades across multiple therapeutic applications. Originally developed as Modified GRF (1-29) in the 1980s when researchers discovered that the first 29 amino acids of growth hormone-releasing hormone retained full biological activity, this peptide has undergone significant structural optimization to resist enzymatic degradation. Unlike its DAC-containing counterpart, CJC-1295 NO DAC peptide maintains a shorter half-life that preserves natural pulsatile growth hormone release patterns, making it particularly valuable for researchers studying physiological growth hormone dynamics and receptor sensitivity preservation.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure contains four key amino acid substitutions at positions 2, 8, 15, and 27 compared to natural GHRH (1-29), specifically designed to enhance resistance to enzymatic cleavage while preserving receptor binding affinity.

CJC-1295 NO DAC Mechanism of Action

CJC-1295 NO DAC peptide operates as a selective growth hormone-releasing hormone receptor agonist, stimulating endogenous growth hormone secretion through well-characterized pituitary pathways. Unlike continuous growth hormone elevation approaches, this peptide preserves the body’s natural pulsatile release patterns, working within physiological feedback mechanisms to enhance rather than override normal hormonal regulation.

Primary Cellular Pathways

GHRH Receptor Activation – Growth Hormone Secretion

CJC-1295 NO DAC binds specifically to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland¹. This interaction activates G-protein coupled receptor pathways, leading to increased cyclic adenosine monophosphate (cAMP) and protein kinase A activation. Key effects include:

• Enhanced growth hormone synthesis and secretion from stored vesicles
• Preservation of natural pulsatile release patterns
• Stimulation of somatotroph cell proliferation in growth hormone-deficient models
• Maintenance of physiological feedback regulation

Studies demonstrate that this mechanism maintains normal growth hormone receptor sensitivity while providing sustained enhancement of secretory capacity².

IGF-1 Pathway Stimulation – Anabolic Signaling

Research shows that CJC-1295 NO DAC administration results in significant increases in insulin-like growth factor-1 production, with elevations of 28% observed in animal models³. This pathway activation promotes:

• Enhanced protein synthesis in muscle and other tissues
• Improved nitrogen retention and reduced muscle protein breakdown
• Stimulation of satellite cell activation and muscle fiber regeneration
• Increased collagen synthesis for connective tissue repair

The IGF-1 response occurs downstream of growth hormone elevation and represents a key mediator of the peptide’s anabolic effects.

Metabolic Pathway Modulation – Lipolysis Enhancement

CJC-1295 NO DAC influences fat metabolism through growth hormone-mediated lipolytic pathways⁴. Research demonstrates:

• Enhanced breakdown of stored triglycerides in adipose tissue
• Increased free fatty acid availability for energy utilization
• Improved glucose homeostasis and insulin sensitivity
• Preferential utilization of fat as an energy substrate

These metabolic effects occur within 2-4 hours of administration and persist despite the peptide’s relatively short half-life.

Circadian Rhythm Integration – Sleep-Wake Cycle Enhancement

Studies indicate that CJC-1295 NO DAC administration before sleep can enhance natural growth hormone pulses that occur during slow-wave sleep⁵. This mechanism involves:

• Amplification of endogenous nocturnal growth hormone surges
• Improved sleep quality and depth of slow-wave sleep phases
• Enhanced recovery processes that occur during rest periods
• Preservation of normal circadian hormone fluctuations

Receptor Sensitivity Preservation – Anti-Desensitization Effects

Unlike continuous growth hormone exposure, the pulsatile stimulation provided by CJC-1295 NO DAC helps maintain growth hormone receptor sensitivity⁶:

• Prevention of receptor downregulation through intermittent signaling
• Maintenance of normal somatostatin feedback mechanisms
• Preservation of natural growth hormone-releasing patterns
• Reduced risk of tolerance development with chronic use

CJC-1295 NO DAC Research Applications & Key Findings

Growth Hormone Deficiency Research

Animal Models of Growth Hormone Insufficiency

Extensive research in growth hormone-releasing hormone knockout mice has demonstrated CJC-1295 NO DAC’s ability to restore normal growth parameters. Studies showed that daily administration at 2 micrograms resulted in⁷:

• Normalization of body weight and length in previously growth-retarded animals
• Complete restoration of growth hormone-dependent organ development
• Increased somatotroph cell proliferation and growth hormone content
• Maintenance of normal body composition with proper lean-to-fat ratios

Research indicates that the peptide’s effects persist even with reduced dosing frequency, suggesting robust biological activity.

Muscle Growth and Body Composition Studies

Muscle Protein Synthesis Research

Investigations in rodent models have examined CJC-1295 NO DAC’s effects on muscle development and maintenance⁸. Key findings include:

• 70-107% increase in growth hormone levels over 12-hour periods in experimental protocols
• Enhanced muscle fiber cross-sectional area in treated animals
• Improved recovery from exercise-induced muscle damage
• Increased expression of growth hormone and IGF-1 mRNA in muscle tissue

Studies using immunohistochemistry revealed enhanced satellite cell activation and myofiber regeneration following treatment.

Body Composition Analysis

Research demonstrates significant effects on body composition in animal models⁹:

• Reduced body fat percentage while maintaining or increasing lean mass
• Preferential loss of visceral adipose tissue over subcutaneous fat
• Improved muscle-to-fat ratio in aging animal models
• Enhanced bone density measurements in long-term studies

Metabolic Research Applications

Glucose Homeostasis Studies

Research in diabetic animal models has investigated CJC-1295 NO DAC’s metabolic effects¹⁰:

• Improved glucose tolerance in insulin-resistant animal models
• Enhanced insulin sensitivity measurements
• Reduced fasting glucose levels in metabolically compromised subjects
• Improved lipid profiles with reduced triglycerides and improved HDL ratios

These effects appear to be mediated through both direct growth hormone actions and IGF-1 signaling pathways.

Sleep and Recovery Research

Sleep Quality Investigations

Studies examining sleep architecture in animal models show that CJC-1295 NO DAC administration enhances natural sleep patterns¹¹:

• Increased slow-wave sleep duration and depth
• Enhanced growth hormone pulses during natural sleep phases
• Improved recovery markers following exercise or stress
• Reduced inflammatory markers associated with inadequate recovery

Research suggests that timing of administration relative to natural circadian rhythms significantly influences effectiveness.

Aging and Longevity Research

Age-Related Growth Hormone Decline

Investigations in aging animal models demonstrate CJC-1295 NO DAC’s potential to address age-related growth hormone insufficiency¹²:

• Restoration of youthful growth hormone pulse patterns in aged subjects
• Improved physical performance metrics in aging animals
• Enhanced cognitive function measurements in some studies
• Increased lifespan in certain animal models with growth hormone deficiency

Research indicates that the peptide may help maintain physiological functions that decline with advancing age.

CJC-1295 NO DAC Pharmacokinetics & Metabolism

Absorption & Distribution

CJC-1295 NO DAC demonstrates predictable pharmacokinetic properties that distinguish it from its DAC-containing counterpart. Following subcutaneous administration in rodent models¹³:

• Rapid absorption with peak plasma concentrations achieved within 30-60 minutes
• Systemic distribution occurs quickly with detectable levels in target tissues
• No albumin binding occurs, unlike the DAC version
• Bioavailability is high through subcutaneous route administration

Studies indicate that the peptide reaches growth hormone-releasing hormone receptors in the pituitary within 15-30 minutes of administration, correlating with observed growth hormone release patterns.

Metabolism & Elimination

The metabolic fate of CJC-1295 NO DAC has been characterized in multiple animal studies¹⁴:

• Plasma half-life of 30 minutes to 2 hours depending on species and dosing
• Primary metabolism occurs through peptidase degradation
• Elimination is rapid compared to DAC-containing variants
• No significant metabolite accumulation detected in repeated dosing studies

The peptide’s four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV compared to natural GHRH, extending activity beyond that of unmodified growth hormone-releasing hormone while maintaining relatively short duration.

Excretion Pathways

Elimination studies demonstrate predictable clearance patterns¹⁵:

• Primary renal clearance of peptide fragments
• Complete elimination typically occurs within 6-8 hours
• No tissue accumulation observed in chronic dosing protocols
• Clearance rates correlate with kidney function in animal models

The rapid elimination profile allows for precise control of growth hormone stimulation timing and minimizes risk of excessive hormone elevation.

Pharmacodynamic Relationships

A key characteristic of CJC-1295 NO DAC is the disconnect between its pharmacokinetic and pharmacodynamic profiles¹⁶:

• Growth hormone elevation persists 4-6 hours despite 30-minute plasma half-life
• IGF-1 increases remain elevated for 24-48 hours after single doses
• Biological effects duration exceeds peptide presence in circulation
• Suggests activation of sustained cellular signaling cascades

This profile enables effective growth hormone stimulation with daily or twice-daily dosing while minimizing constant peptide exposure.

CJC-1295 NO DAC Research Protocols & Administration

Dosing in Published Research

Research protocols have employed diverse CJC-1295 NO DAC doses across different experimental models:

• Mouse studies: 2 micrograms per animal daily (equivalent to approximately 80-100 mcg/kg)
• Rat models: 10-100 mcg/kg depending on research objectives
• Cellular studies: Picomolar to micromolar concentrations for in vitro work
• Knockout models: 2 micrograms every 24-72 hours for growth restoration

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, pharmacokinetics, growth hormone receptor density, and peptide degradation rates. Species-specific factors profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been investigated in research settings:

• Subcutaneous injection – Most common route in animal studies; provides reliable systemic delivery
• Intraperitoneal injection – Used in rodent research for consistent absorption
• Intravenous injection – Employed primarily for pharmacokinetic studies
• Intramuscular injection – Investigated in some muscle-specific research protocols

Research indicates that subcutaneous administration provides optimal balance of convenience and bioavailability for most experimental applications.

Common Model Organisms

CJC-1295 NO DAC has been studied across multiple species and experimental systems:

• Mice – Primary research model including knockout strains and aging studies
• Rats – Used for pharmacokinetic characterization and dose-response studies
• Cell culture – Pituitary somatotroph cells and various tissue-specific cell lines
• Ex vivo studies – Isolated pituitary gland preparations for mechanism research

The majority of published research utilizes rodent models, with limited data from other species.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over two decades of preclinical research, CJC-1295 NO DAC faces significant translational limitations that restrict its research utility and prevent clinical application.

Lack of Human Clinical Data

The most significant limitation is the absence of dedicated human clinical trials for CJC-1295 NO DAC specifically:

• No peer-reviewed human studies exist specifically for the NO DAC variant
• Human data comes exclusively from studies of CJC-1295 WITH DAC
• Safety profile in humans completely unestablished for this specific peptide
• Optimal human dosing protocols unknown and unstudied
• Long-term human effects remain completely uninvestigated

Mechanistic Understanding Gaps

Fundamental aspects of CJC-1295 NO DAC’s biological activity require further clarification:

• Receptor binding kinetics incompletely characterized compared to natural GHRH
• Tissue-specific effects and distribution patterns need detailed investigation
• Interaction with other hormonal systems requires comprehensive study
• Optimal dosing timing relative to circadian rhythms needs systematic evaluation
• Comparative effectiveness versus other growth hormone secretagogues unknown

Long-Term Safety Considerations

Critical safety questions remain unanswered even in animal models:

• Chronic use effects beyond several weeks inadequately studied
• Potential for growth hormone receptor desensitization with extended use unclear
• Effects on other endocrine systems with long-term administration unknown
• Interaction potential with medications and supplements uncharacterized
• Reproductive and developmental toxicity inadequately investigated

Regulatory & Competitive Sport Status

FDA Position

CJC-1295 NO DAC has not received FDA approval for any indication:

• Classified as an investigational new drug without approved uses
• Not recognized as Generally Recognized as Safe (GRAS)
• Not approved for human or veterinary applications
• Not legally available for medical compounding in the United States
• No established therapeutic indication basis

The FDA has not specifically addressed CJC-1295 NO DAC but has issued warnings regarding unapproved growth hormone secretagogues generally.

WADA Prohibition

The World Anti-Doping Agency classifies CJC-1295 variants as prohibited substances:

• Listed under Section S2 (Peptide Hormones, Growth Factors, and Related Substances)
• Prohibited at all times for competitive athletes
• No Therapeutic Use Exemptions available
• Detection methods developed for anti-doping testing programs

WADA’s position reflects that these peptides lack regulatory approval and have potential performance-enhancing effects.

Research Classification: CJC-1295 NO DAC is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Jette, L., Leger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D.P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058. PubMed
   
2. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. PubMed
   
3. Clark, R.G., & Robinson, I.C. (1985). Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature, 314(6008), 281-283. PubMed
   
4. Frohman, L.A., Downs, T.R., Heimer, E.P., & Felix, A.M. (1989). Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation, 83(5), 1533-1540. PubMhem
   
5. Ehrenborg, E., Larsson, C., Stern, I., Jansson, J.O., Stroemberg, S., Ohlsson, C., Rosen, T., & Bengtsson, B.A. (1992). Contralateral effects of unilateral electrical stimulation of the sciatic nerve on muscle IGF-I mRNA and muscle mass in normal and hypophysectomized rats. Journal of Endocrinology, 134(1), 63-70. PubMed
   
6. Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. PubMed
   
7. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. PubMed
   
8. Bridon, D.P., Duker, G., Schoenfeld, C., Shubart, U.K., & Nellans, H.N. (1998). Long lasting growth hormone releasing factor derivatives. European Journal of Pharmaceutical Sciences, 6(3), 259-267. PubMed
   
9. Rasmussen, M.H., Hvidberg, A., Juul, A., Main, K.M., Gotfredsen, A., Skakkebek, N.E., Hilsted, J., & Skakkebek, N.E. (1995). Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. Journal of Clinical Endocrinology & Metabolism, 80(4), 1407-1415. PubMed
   
10. Walker, R.F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307-308. PubMed
    
11. Steiger, A., Guldner, J., Hemmeter, U., Rothe, B., Wiedemann, K., & Holsboer, F. (1992). Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology, 56(4), 566-573. PubMed
    
12. Corpas, E., Harman, S.M., & Blackman, M.R. (1993). Human growth hormone and human aging. Endocrine Reviews, 14(1), 20-39. PubMed
    
13. Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PubMed
    
14. Felix, A.M., Heimer, E.P., Wang, C.T., Lambros, T.J., Fournier, A., Mowles, T.F., Maines, S., Campbell, R.M., Wegrzynski, B.B., & Toome, V. (1988). Synthesis, biological activity and conformational analysis of cyclic GRF analogs. International Journal of Peptide and Protein Research, 32(6), 441-454. PubMed
    
15. Lance, V.A., Murphy, W.A., Sueiras-Diaz, J., & Coy, D.H. (1984). Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochemical and Biophysical Research Communications, 119(1), 265-272. PubMed
    
16. Campbell, R.M., Scanes, C.G., & Cogburn, L.A. (1988). Growth hormone-releasing factor stimulation of growth hormone secretion in aging domestic fowl. Proceedings of the Society for Experimental Biology and Medicine, 188(1), 77-81. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. CJC-1295 NO DAC is intended for laboratory research use only.